Residency · Residency · Neurology

Dementia with Lewy Bodies and Parkinson Disease Dementia

Introduction

Dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD) represent two clinical expressions of the same underlying alpha-synuclein pathology, collectively termed Lewy body dementias. DLB is the second most common neurodegenerative dementia after Alzheimer disease, yet it remains significantly underdiagnosed. Accurate recognition is essential because patients with Lewy body dementia have characteristic treatment responses and unique sensitivities to neuroleptic medications.

Pathophysiology

The pathological hallmark is aggregation of alpha-synuclein into intraneuronal Lewy bodies and Lewy neurites. Lewy pathology spreads in a caudal-to-rostral pattern through the nervous system, as described by Braak staging for Parkinson disease, progressing from the medulla and olfactory bulb through the brainstem, limbic system, and ultimately to the neocortex. In DLB, cortical Lewy pathology is prominent early, while in PDD, cortical involvement occurs later after years of predominantly brainstem disease. Coexisting Alzheimer pathology (amyloid plaques) is common in DLB, present in 50-80% of cases, and contributes to cognitive decline. Cholinergic deficits are more severe in DLB than in AD, reflecting degeneration of the nucleus basalis of Meynert.

Clinical Features of DLB

Core Clinical Features (2017 Consensus Criteria)

The four core features are fluctuating cognition, recurrent visual hallucinations, REM sleep behavior disorder, and parkinsonism. Fluctuating cognition manifests as spontaneous variations in attention and alertness, with episodes of staring, disorganized speech, or drowsiness alternating with periods of near-normal function. Visual hallucinations are well-formed and detailed, often depicting people or animals, and are typically non-threatening early in the disease; patients may retain partial insight. REM sleep behavior disorder involves dream enactment behavior and may precede cognitive symptoms by years to decades. Parkinsonism features bradykinesia, rigidity, and resting tremor (less prominent than in PD), with postural instability and a typically symmetric or mildly asymmetric distribution. Two or more core features establish probable DLB, while one core feature yields possible DLB.

Supportive Clinical Features

Supportive features include severe sensitivity to antipsychotic medications (neuroleptic sensitivity), postural instability with repeated falls, syncope or transient episodes of unresponsiveness, and severe autonomic dysfunction (orthostatic hypotension, urinary incontinence, constipation). Hypersomnia, hyposmia, depression, anxiety, apathy, and delusions (often paranoid or misidentification type) are also commonly observed.

Indicative Biomarkers

Three indicative biomarkers carry significant diagnostic weight. Reduced dopamine transporter uptake in the basal ganglia on DaT-SPECT or PET (DaTscan) has high specificity for Lewy body pathology. Polysomnographic confirmation of REM sleep without atonia provides objective evidence. Reduced cardiac sympathetic innervation on 123I-MIBG myocardial scintigraphy is another supportive finding. One or more indicative biomarkers combined with one or more core features establishes probable DLB.

Parkinson Disease Dementia

Diagnostic Distinction from DLB

The "one-year rule" is used to distinguish DLB from PDD as a clinical convention. In DLB, cognitive symptoms develop before or within one year of parkinsonism onset, while in PDD, dementia develops more than one year after the onset of well-established motor Parkinson disease. This distinction is clinical rather than pathological, as the underlying pathology exists on a spectrum. PDD affects 50-80% of PD patients over the disease course, with risk increasing with age, severity of motor disease, and certain features such as early hallucinations, RBD, and postural instability.

Cognitive Profile of PDD

The cognitive profile features prominent executive dysfunction, impaired attention, and visuospatial deficits. Memory impairment is characterized by retrieval deficits that improve with cueing, unlike the encoding deficit seen in AD. Visuoperceptual disturbances are common, and cognitive fluctuations and hallucinations resemble those of DLB.

Neuroimaging

MRI shows relative preservation of medial temporal lobe volume compared to AD, which is an important distinguishing feature, though posterior cortical atrophy may be seen. FDG-PET demonstrates occipital hypometabolism, including the primary visual cortex, which distinguishes DLB from AD (which spares the occipital cortex). The "cingulate island sign" (preserved posterior cingulate metabolism relative to the precuneus) is characteristic. Amyloid PET is positive in approximately 50-80% of DLB cases, reflecting coexisting AD pathology; a positive amyloid PET does not exclude DLB. DaT-SPECT (DaTscan) shows reduced striatal dopamine transporter uptake and helps distinguish DLB from AD, for which it is FDA approved.

Treatment

Cognitive Symptoms

Cholinesterase inhibitors are the cornerstone of treatment, and DLB patients often show a robust response due to the severity of their cholinergic deficits. Rivastigmine has the strongest evidence in both oral and transdermal formulations and is also effective for PDD. Donepezil is also used but may slightly worsen parkinsonism and requires monitoring. Memantine may be added for moderate-to-severe disease.

Neuropsychiatric Symptoms

For visual hallucinations, the first step is to determine whether they cause distress, as benign hallucinations may not require treatment. When intervention is needed, reducing or eliminating anticholinergic and dopaminergic medications cautiously is the first approach. Pimavanserin, a serotonin 5-HT2A inverse agonist FDA-approved for PD psychosis, is considered for DLB as well. Quetiapine at low doses (12.5-50 mg) is the most commonly used atypical antipsychotic if needed, though evidence is limited. Clozapine is effective but requires blood monitoring for agranulocytosis. Haloperidol, risperidone, and olanzapine must be avoided, as they can cause severe and potentially fatal neuroleptic sensitivity reactions with marked worsening of parkinsonism, rigidity, and obtundation. Depression is treated with SSRIs such as sertraline or citalopram, avoiding tricyclics due to their anticholinergic burden. Agitation is managed with non-pharmacological interventions first, followed by low-dose quetiapine if necessary.

Motor Symptoms

Levodopa/carbidopa may improve parkinsonism but can worsen hallucinations and psychosis, so it should be started at low doses and titrated slowly. Dopamine agonists should be avoided because of the higher risk of hallucinations and impulse control disorders. Physical therapy and fall prevention are essential.

REM Sleep Behavior Disorder

Melatonin at doses of 3-12 mg at bedtime is the first-line treatment. Low-dose clonazepam may be used if melatonin is insufficient, though caution is warranted due to fall risk.

Autonomic Dysfunction

Orthostatic hypotension is managed with fludrocortisone, midodrine, or droxidopa, along with non-pharmacological measures including compression stockings, adequate hydration, and salt supplementation. Constipation is addressed with fiber, polyethylene glycol, and exercise. For urinary symptoms, other causes should be evaluated first, and mirabegron is preferred over anticholinergic agents.

Clinical Pearls

Neuroleptic sensitivity is a defining feature of DLB; typical antipsychotics and high-potency atypical antipsychotics are contraindicated and can precipitate a life-threatening crisis resembling neuroleptic malignant syndrome. Cholinesterase inhibitors, especially rivastigmine, often produce a more robust cognitive benefit in DLB than in AD due to the severity of cholinergic deficits. REM sleep behavior disorder may precede dementia in DLB by a decade or more, and its presence in a patient developing cognitive symptoms strongly supports a Lewy body etiology. A normal DaTscan effectively excludes DLB from the differential diagnosis in a patient with dementia, while a positive scan distinguishes DLB from AD with high specificity. Occipital hypometabolism on FDG-PET is characteristic of DLB and is not seen in typical AD, a pattern that may explain the prominent visual hallucinations.

References

1. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100.
2. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22(12):1689-1707.
3. Taylor JP, McKeith IG, Burn DJ, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19(2):157-169.
4. Cummings J, Pinto LC, Cruz M, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomized, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533-540.

Read this lecture as Markdown